PubRank

C A Meyers

Author PubWeight™ 83.06‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem 1983 9.32
2 Purification and initial characterization of a type beta transforming growth factor from human placenta. Proc Natl Acad Sci U S A 1983 3.52
3 Purification and properties of a type beta transforming growth factor from bovine kidney. Biochemistry 1983 3.49
4 Synergistic interaction of two classes of transforming growth factors from murine sarcoma cells. Cancer Res 1982 2.70
5 The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 1995 2.55
6 Synthetic peptides corresponding to keratin subunits elicit highly specific antibodies. J Biol Chem 1984 1.96
7 Cognitive functioning and quality of life in malignant glioma patients: a review of the literature. Psychooncology 1997 1.87
8 A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002 1.73
9 Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurology 1995 1.71
10 Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas. Int J Radiat Oncol Biol Phys 2002 1.61
11 Hypothalamic regulatory hormones. Annu Rev Biochem 1978 1.60
12 Klüver-Bucy syndrome after bilateral selective damage of amygdala and its cortical connections. J Neuropsychiatry Clin Neurosci 1998 1.59
13 Recombinant HIV-1 reverse transcriptase: purification, primary structure, and polymerase/ribonuclease H activities. Arch Biochem Biophys 1989 1.41
14 Vav cooperates with Ras to transform rodent fibroblasts but is not a Ras GDP/GTP exchange factor. Oncogene 1994 1.30
15 Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol 1998 1.16
16 Purification and characterization of human recombinant interleukin-1 beta. J Biol Chem 1987 1.16
17 Neuropsychological dysfunction associated with cancer and cancer therapies: a conceptual review of an emerging target. Br J Cancer 2004 1.15
18 Postoperative mutism in neurosurgery. Report of two cases. J Neurosurg 1994 1.13
19 Highly active position eight analogues of somatostatin and separation of peptide diastereomers by partition chromatography. Biochemistry 1978 1.07
20 Relationship between quality of life and mood in long-term survivors of breast cancer treated with mastectomy. Support Care Cancer 1997 1.07
21 Synthesis and biological actions of prosomatostatin. Proc Natl Acad Sci U S A 1980 1.07
22 A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor. J Neurooncol 2011 1.05
23 Orientation of peptide fragments from Sos proteins bound to the N-terminal SH3 domain of Grb2 determined by NMR spectroscopy. Biochemistry 1994 1.02
24 Treatment of neurotoxic side effects of interferon-alpha with naltrexone. Cancer Invest 1995 0.98
25 Solution structure of the Grb2 N-terminal SH3 domain complexed with a ten-residue peptide derived from SOS: direct refinement against NOEs, J-couplings and 1H and 13C chemical shifts. J Mol Biol 1997 0.98
26 A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin Cancer Res 1997 0.98
27 Psychosocial functioning and quality of life in patients with primary brain tumors. J Neurosurg 1996 0.94
28 Ventricular enlargement after closed head injury. Arch Neurol 1981 0.94
29 Cognitive dysfunction following surgery for intracerebral glioma: influence of histopathology, lesion location, and treatment. J Neurooncol 1996 0.93
30 Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. Int J Radiat Oncol Biol Phys 1995 0.92
31 Developing a care giver quality-of-life instrument. Preliminary steps. Cancer Pract 1997 0.92
32 Cognitive and mood disturbance as causes and symptoms of fatigue in cancer patients. Cancer 2001 0.90
33 Potent, highly selective inhibition of growth hormone secretion by position 4 somatostatin analogs. Endocrinology 1981 0.90
34 Secretion of N-glycosylated interleukin-1 beta in Saccharomyces cerevisiae using a leader peptide from Candida albicans. Effect of N-linked glycosylation on biological activity. J Biol Chem 1991 0.90
35 Methylphenidate in the treatment of neurobehavioral slowing associated with cancer and cancer treatment. J Neuropsychiatry Clin Neurosci 1995 0.89
36 A retrospective study of the psychiatric management and outcome of delirium in the cancer patient. Support Care Cancer 1996 0.89
37 The hippocampus: normal anatomy and pathology. AJR Am J Roentgenol 1998 0.88
38 NGF gene transfer to intrinsic basal forebrain neurons increases cholinergic cell size and protects from age-related, spatial memory deficits in middle-aged rats. Brain Res 2000 0.88
39 Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma. Anticancer Drugs 1998 0.86
40 Prophylactic treatment of depression induced by interferon-alpha. Psychosomatics 2000 0.86
41 Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity. J Med Chem 1996 0.86
42 Structure-activity studies with somatostatin: the role of tryptophan in position 8. Regul Pept 1980 0.85
43 Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: inclusion of quality of life and other patient-reported outcomes. Crit Rev Oncol Hematol 2011 0.85
44 Efficacy of postacute brain injury rehabilitation for patients with primary malignant brain tumors. Cancer 1997 0.84
45 Mutism after closed head injury. Arch Neurol 1983 0.84
46 Transforming growth factors from a human tumor cell: characterization of transforming growth factor beta and identification of high molecular weight transforming growth factor alpha. Biochemistry 1985 0.83
47 Linguistic recovery after closed head injury. Brain Lang 1981 0.82
48 The multisubunit IkappaB kinase complex shows random sequential kinetics and is activated by the C-terminal domain of IkappaB alpha. J Biol Chem 1998 0.82
49 Early versus late lateral ventricular enlargement following closed head injury. J Neurol Neurosurg Psychiatry 1983 0.82
50 Activity of VIP, somatostatin and other peptides in the mouse vas deferens assay. Pharmacol Biochem Behav 1978 0.81
51 [Phe4]somatostatin: a potent, selective inhibitor of growth hormone release. Proc Natl Acad Sci U S A 1980 0.81
52 Selective inhibition of glucagon and insulin secretion by somatostatin analogs. Proc Soc Exp Biol Med 1979 0.80
53 Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer. Cancer Chemother Pharmacol 2000 0.80
54 Somatostatin, basic and clinical studies. A review. Mater Med Pol 1982 0.79
55 Gastrointestinal secretory, motor, circulatory, and metabolic effects of prosomatostatin. Proc Natl Acad Sci U S A 1981 0.79
56 Medical problems encountered during rehabilitation of patients with head injury. Arch Phys Med Rehabil 1985 0.78
57 Effects of prosomatostatin on growth hormone and prolactin response to arginine in man. Comparison with somatostatin. Lancet 1981 0.78
58 Effect of human pancreatic polypeptide and its C-terminal hexapeptide on pancreatic secretion in man and in the dog. Scand J Gastroenterol 1982 0.78
59 Selective effect of some somatostatin analogs on glucagon as opposed to insulin release in rats in vivo. Metabolism 1980 0.78
60 Human pancreatic polypeptide inhibits insulin release in the rat. Biochem Biophys Res Commun 1981 0.78
61 Immunocytochemical localization of CRF in the ovine hypothalamus. Peptides 1982 0.77
62 Manic episodes in two patients treated with interferon alpha. J Neuropsychiatry Clin Neurosci 1997 0.77
63 Micelle-bound conformational preferences of a peptide derived from a murine major histocompatibility complex class I molecule. J Biol Chem 1993 0.77
64 Secretion of interleukin-1 beta and Escherichia coli galactokinase by Streptomyces lividans. J Bacteriol 1988 0.77
65 Use of the mouse vas deferens assay to evaluate the action of somatostatin peptides on gastric acid secretion. Digestion 1981 0.76
66 Impairment of remote memory after closed head injury. J Neurol Neurosurg Psychiatry 1985 0.76
67 Successful treatment of interferon-alpha-induced mood disorder with nortriptyline. Psychosomatics 1995 0.76
68 Peptides corresponding to the N and C termini of IkappaB-alpha, -beta, and -epsilon as probes of the two catalytic subunits of IkappaB kinase, IKK-1 and IKK-2. J Biol Chem 1999 0.76
69 A pseudopeptide incorporating the tetrahydrophthalazine nucleus, a constrained aza analog of phenylalanine. Int J Pept Protein Res 1996 0.75
70 Inhibition of growth hormone and glucagon release by Phe-4-somatostatin in patients with acromegaly. Res Commun Chem Pathol Pharmacol 1984 0.75
71 Suppression of somatostatin levels in the hepatic portal and systemic plasma of the rat by synthetic human pancreatic polypeptide. Biochem Biophys Res Commun 1979 0.75
72 The opioid mechanism of interferon-alpha action. Anticancer Drugs 1994 0.75
73 Differentiation of somatostatin receptors involved in inhibition of gastric acid and growth hormone secretion with halogenated Trp8 analogues [proceedings]. J Physiol 1978 0.75
74 Neurochemical basis of interleukin 2-modified discrimination behaviour. Cytokine 1994 0.75
75 Introduction to hippocampal spectroscopy. Neuroimaging Clin N Am 1997 0.75
76 Quality of life and neurobehavioural functioning in patients with malignant gliomas. Baillieres Clin Neurol 1996 0.75
77 St. Ansgar Hospital, Moorhead, MN. Volunteer-staffed center supervises visitors', outpatients' children. Hosp Prog 1981 0.75
78 Solid-phase synthesis of human pancreatic polypeptide. Int J Pept Protein Res 1980 0.75
79 Selective inhibition of sleep related growth hormone release by Phe-4-somatostatin. Res Commun Chem Pathol Pharmacol 1984 0.75
80 Sensitive radioimmunoassay for somatostatin using N-[125I]-Tyr-somatostatin as labelled antigen. Clin Endocrinol (Oxf) 1979 0.75